T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy

World Journal of Surgical Oncology

Kwan Hee Hong¹  Min Kyung Oh²  Mi Seon Kang³  Bo Mi Kim³  Ji Hyun Kim⁴  Jin Won Hwang⁴  Chang Soo Choi¹  Ki Beom Bae¹  Kwang Hee Kim¹  Jong Han Yoo¹  Min Sung An¹ 

[1] Department of Surgery, Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu 614-735, Busan, Korea;Clinical Trial Center in Pharmacology, Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu 614-735, Korea;Pathology, Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu 614-735, Korea;Internal medicine, Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu 614-735, Korea

关键词: Anemia;    T4 stage;    FOLFOX;    Colon cancer;   

Others  :  1131017
DOI  :  10.1186/s12957-015-0488-7

 received in 2014-05-29, accepted in 2015-01-26,  发布年份 2015

【 摘 要 】

Background

FOLFOX-based adjuvant chemotherapy is a benefit for high-risk stage II and stage III colon cancer after curative resection. But, the prognostic factor or predictive marker for the efficacy of FOLFOX remains unclear. This study was aimed to identify the prognostic value and cumulative impact of adjuvant FOLFOX on the stage II and III colon cancer patients.

Methods

A total of 196 stage II and III colon cancer patients were retrospectively enrolled in prospectively collected data. They underwent curative resection followed by FOLFOX4 adjuvant chemotherapy. The oncological outcomes included the 5-year disease-free survival (DFS) rate and 5-year overall survival (OS) rate. Cox-regression analysis was performed to identify the prognostic value, and its cumulative impact was analyzed.

Results

The 5-year DFS rate of the patients was 71.94% and the 5-year OS rate was 81.5%. The prognostic values for the 5-year DFS rate and 5-year OS rate were T4 stage and preoperative anemia in a multivariate analysis. Each patient group who had no prognostic value, single, or both factors revealed 95.35%, 69.06%, and 28.57% in the 5-year DFS rate, respectively (p < 0.0001). The 5-year OS rate also showed the significant differences in each group who had no prognostic value, single, or both factors revealed 100%, 79.3%, and 45.92%, respectively (p < 0.0001).

Conclusion

Our results showed similar efficacy to MOSAIC study in stage II and stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy after curative resection. Patients who had T4 stage and/or preoperative anemia showed worse prognosis than patients without any prognostic value. These findings suggest that FOLFOX could not be effective in the patients with T4 stage colon cancer accompanied by preoperative anemia.

【 授权许可】

   
2015 An et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jung KW, Park SH, Won YJ, Kong HJ, Lee JY, Seo HG, et al.: Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat 2012, 44(1):25-31.
• [2]Obrand DI, Gordon PH: Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997, 40:15-24.
• [3]O’Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004, 96:1420-5.
• [4]O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997, 15:246-60.
• [5]Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990, 322:352-8.
• [6]Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: result from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993, 11:1879-87.
• [7]Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003, 21:2896-903.
• [8]Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004, 350:2343-51.
• [9]Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009, 27:3109-16.
• [10]NCCN Clinical Practice Guidelines in Oncology Colon Cancer version 3. 2014
• [11]Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007, 25:2198-204.
• [12]Andre T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, et al.: Adjuvant treatment of colon cancer MOSAIC study’s main results. Bull Cancer. 2006, 93(Suppl 1):S5-9.
• [13]Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al.: Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011, 29:3768-74.
• [14]McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008, 67(3):257-62.
• [15]Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al.: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007, 18:886-91.
• [16]Snaebjornsson P, Coupe VM, Jonasson L, Meijer GA, van Grieken NC, Jonasson JG: pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd’s local peritoneal involvement revisited. Int J Cancer 2014, 135:467-78.
• [17]Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010, 28:264-71.
• [18]Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001, 91:2214-21.
• [19]Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, et al.: Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys. 2003, 56:778-87.
• [20]Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W, Strebhardt K, et al.: Pre-treatment haemoglobin level predicts response and survival after TPE induction polychemotherapy in advanced head and neck cancer patients. Clin Otolaryngol. 2008, 33:245-51.
• [21]Rades D, Schild SE, Bahrehmand R, Zschenker O, Alberti WA, Rudat VR: Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer. 2005, 103:1740-6.
• [22]Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, et al.: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumor Biol. 2010, 31:255-60.
• [23]Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999, 340:248-54.
• [24]Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al.: Direct regulation of TWIST by HIF-1 alpha promotes metastasis. Nat Cell Biol. 2008, 10:295-305.